ebopiprant (OBE022) / Organon, Xoma - LARVOL DELTA

Efficacy and safety of ebopiprant to delay preterm birth after oral administration in pregnant women with spontaneous preterm labor receiving atosiban: a phase 2a, double-blind, parallel group, randomized, placebo-controlled, proof of concept study. (PubMed, Eur J Obstet Gynecol Reprod Biol) - P2a | "Ebopiprant added to atosiban infusion may reduce the probability of delivering within 48 h."

Journal • P2a data • IGFBP1

Prostaglandin F2α Regulates Adipogenesis by Modulating Extracellular Signal-Regulated Kinase Signaling in Graves' Ophthalmopathy. (PubMed, Int J Mol Sci) - "We used Ebopiprant (FPR antagonist) to interfere with PGF2α binding to the FPR and U0126, an Extracellular Signal-Regulated Kinase (ERK) inhibitor, to inhibit ERK phosphorylation...Overall, PGF2α mediated the inhibitory effect of the OFs adipogenesis through the hyperactivation of ERK phosphorylation via coupling with the FPR. Our study provides a further theoretical reference for the potential application of PGF2α in patients with GO."

Journal • Glaucoma • Lipodystrophy • Ophthalmology • Thyroid Eye Disease • FABP4 • PPARG

Targeting Angiogenesis Receptors in Retinoblastoma: New Treatment Opportunities. (PubMed, FASEB J) - "In order to determine if these proteins can be targeted, we executed several protein-ligand induced fit docking simulations using curcumin, OBE022, and AL-8810. Our simulations demonstrate that these pharmacologic agents can bind efficiently and therefore may assist in the inhibition of angiogenesis."

Journal • Eye Cancer • Oncology • Retinal Disorders • Retinoblastoma • Solid Tumor